Posts Record Revenue, Eyes Continued Growth

Published: 11/6/2024

Author: FRC Analysts

*See important disclosures at the bottom of this report

Sector: Healthcare | Industry: Drug Manufacturers-Specialty & Generic

Ticker Symbols:

DHBUF - NASDAQ 🔹

DHB.V - TSX 🔹

Rating and Key Data

Subscribe for free to get exclusive insights and data.

FY2024 (ended June 2024) revenue was up 26% YoY, coming in just 0.5% below our estimate. This growth was driven by robust U.S. sales of Dream Water products, boosted by expanded distribution points and new product launches, including Dream Water Sleep Gummies and Dream Water Immunity Shots.
DHB sells sleep aid products through its Dream Water brand, and pain relief products through its LivRelief and LivRelief Infused brands. In FY2024, 74% of sales came from the U.S., and the Middle East (FY2023: 68%), and 26% from Canada.

Products are available at 30k+ distribution points including established retail/pharmacy chains such as Shoppers Drug Mart, Walmart (NYSE: WMT), Kroger (NYSE: KR), Sobeys (TSX: EMP), and onli

Rating and Key Data